About the Program
Program Overview
While an increasing number of options exist for treating patients with HIV infection, many clinicians find it difficult to keep abreast of important developments in HIV therapeutics, which can result in suboptimal patient care. This 1.5-hour Live Internet symposium will review and discuss the key studies on antiretroviral therapy presented at the 22nd Conference on Retroviruses and Opportunistic Infections (CROI 2015). The expected result is that clinicians who participate in this program will be better prepared to address HIV-positive patients' health needs and that patients will be more likely to receive optimal care, which should improve antiretroviral adherence, increase the delivery of individualized care, reduce resistance and treatment failure, and improve patient quality of life.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at CROI 2015 and it is not sanctioned by the orgainzers of CROI 2015.
Target Audience
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.
Learning Objectives
After completing this activity, participants should be better able to:
- Use in a clinical setting findings from key new studies on HIV/AIDS diagnosis, management and treatment presented at CROI 2015
- Employ the current treatment paradigms for HIV/AIDS, including the studies and data presented at CROI 2015 to improve patient care
- Discuss with patients and colleagues the studies and data on newer therapies for HIV/AIDS presented at CROI 2015 and use that discussion to decide on appropriate planning of therapy for patients with HIV/AIDS
Back to Top
Faculty
José Arribas, MD
Research Director (AIDS and Infectious Diseases)
Hospital de La Paz
Madrid, Spain
Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom
Jürgen Rockstroh, MD
Professor
University of Bonn
Bonn, Germany
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
The Postgraduate Institute for Medicine (PIM) requires instructors,
planners, managers and other individuals who are in a position to
control the content of this activity to disclose any real or apparent
conflict of interest (COI) they may have as related to the content of
this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. The existence or absence of COI for everyone in
a position to control content will be disclosed to participants prior
to the start of each activity.
Jose Arribas, MD
- Consulting Fees: ViiV, Tibotec, Janssen, Abbvie, BMS, Gilead, MSD
Ian Frank, MD
- Consulting Fees: Gilead, ViiV
- Contracted Research: GSK, Bavarian Nordic
- Other (expert testimony): Janssen
Graeme Moyle, MD
- Consulting Fees: Merck, BMS, Teva
- Fees for Non-CME/CE Services: Merck, BMS, Gilead Sciences, Janssen, ViiV Healthcare
- Ownership Interest: Tobira
- Other: Board Membership - Tobira
Juergen Rockstroh, MD
- Consulting Fees: Abbvie, Bionor, BMS, Gilead, Janssen, Merck, ViiV
- Fees for Non-CME/CE Services: Abbvie, BMS, Gilead, Janssen, Merck, ViiV
- Contracted Research: Gilead
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period, March 4, 2015 through March 4, 2016, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If
you wish to received acknowledgment of completing this activity, please
complete the post-test and evaluation on www.cmeuniveristy.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 10496.
Upon registering and successfully completing the post-test with a score
of 70% or better and the activity evaluation, your certificate will be
made available immediately. Processing credit requests online will
reduce the amount of paper used by nearly 100,000 sheets per year.
Disclosure of Unlabeled Use
This
educational activity may contain discussion of published and/or investigational
uses of agents that are not indicated by the FDA. The planners of this activity
do not recommend the use of any agent outside of the labeled indications.
The
opinions expressed in the educational activity are those of the faculty and do
not necessarily represent the views of the planners. Please refer to the
official prescribing information for each product for discussion of approved
indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.
|